Cetaphil
Phase 3Small molecule
Cetaphil is one of 46 small molecule programs targeting Efficacy. It is currently in Phase 3.
1
Indications
5
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
145 competitors in Efficacy
#DrugCompanyPhaseTrials
1Tivicay
GSKPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Alimta
SShawn Eagle
Phase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Insulin 320
Novo NordiskPhase 3
Zelhou
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 3
Pifeltro
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
QL2107
Qilu Pharmaceutical Co., Ltd.Phase 3
Endothelin Receptor Antagonist
RRadboud University Medical Center
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dialysis Patients1 trial
Treatment1 trial
Treatment of Prepubertal Labial Adhesions
Completed·—·N/A·NCT02218463·43 enrolled
Efficacy1 trial
Psoriasis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cetaphil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- GGalderma R&D